Pepsanurina en la insuficiencia cardíaca congestiva / Pepsanurin in congestive heart failure
Rev. méd. Chile
;
119(2): 137-41, feb. 1991. ilus
Article
Dans Espagnol
| LILACS
| ID: lil-98195
ABSTRACT
We have identified a plasmatic substance, "pepsanurin" (PU) obtained by pepsin hydrolysis which inhibits the renal effects of the atrial natriuretic factor (ANF). To investigate whether patients with congestive heart failure (CHF) have increased plasma levels of PU we prepared PU from 10 patients with CHF class IV (NYHA), 9 patients with CHF class II or III and 16 healthy controls. Anesthetized rats were used to test the effects of ANF, 0.5 ug/100 g body weight i.v., before and following the intraperitoneal injection of 0.5 ml of PU. The inhibition of the diuretic and natriuretic effects of ANF was 40.9 ñ 11.9% and 49.8 ñ 12% respectively for control subjects. Corresponding figures for clas CHF patients were 62.3 ñ 3.1% and 73.8 ñ 3.5% (p < 0.02) and for class II-III patients 39.2 ñ 7.0% and 53.1 ñ 8.2% (NS). Accordingly, an increased capacity to generate PU may underlie the decreased sensitivity to ANF in patients with advanced CHF
Recherche sur Google
Indice:
LILAS (Amériques)
Sujet Principal:
Pepsine A
/
Facteur atrial natriurétique
/
Défaillance cardiaque
/
Rein
/
Natriurèse
Type d'étude:
Étude pronostique
Limites du sujet:
Animaux
/
Femelle
/
Humains
langue:
Espagnol
Texte intégral:
Rev. méd. Chile
Thème du journal:
Médicament
Année:
1991
Type:
Article
/
descriptif de projet
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS